-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 24 , 2022 , the Chinese Society of Clinical Oncology (CSCO) officially released the " Practice Guidelines for Tumor - Associated Anemia 2022 " .
On April 24 , 2022 , the Chinese Society of Clinical Oncology (CSCO) officially released the " Practice Guidelines for Tumor - Associated Anemia 2022 " .
Compared with the 2021 version of the guidelines , this update mainly focuses on three parts: hematopoietic malignancies, EPO ( human erythropoietin / recombinant human erythropoietin for short , the same below ) dose and dose adjustment, intravenous iron use , and treatment.
Compared with the 2021 version of the guidelines , this update mainly focuses on three parts: hematopoietic malignancies, EPO ( human erythropoietin / recombinant human erythropoietin for short , the same below ) dose and dose adjustment, intravenous iron use , and treatment.
First , in the treatment principle of tumor-related anemia - hematopoietic malignancies (3.
Secondly , in the treatment of tumor-related anemia - EPO dose and dose adjustment (4.
Third , in the treatment of tumor-related anemia - dosage, route and precautions of intravenous iron (4.
36000 U once a week to become a level I recommended new regimen for MDS
36000 U 36000 U once a week to become a weekly MDS MDS level II recommended new program level recommended new programFor MDS , the 2021 version of the guidelines only recommends " subcutaneous injection of EPO 40 000-60 000U , 1-2 times a week " for the treatment of anemia in low-intermediate risk MDS .
For MDS , the 2021 version of the guidelines only recommends " subcutaneous injection of EPO 40 000-60 000U , 1-2 times a week " for the treatment of anemia in low-intermediate risk MDS .
Professor Chen Wenming of Beijing Red Cross Chaoyang Hospital Affiliated to Capital Medical University said : "EPO has always been an effective drug for the treatment of MDS anemia , but because it is in the form of injection and needs to be used almost every day , some patients have poor compliance .
Professor Zhou Yuhong of Zhejiang Provincial Hospital of Traditional Chinese Medicine said : "EPO is one of the main drugs for the clinical treatment of anemia caused by a variety of diseases , especially in patients with anemia caused by low / intermediate risk myelodysplastic syndromes .
The initial dose of EPO EPO is increased .
In the previous version of the guideline , the recommended regimens of EPO were all subcutaneous injections.
Professor Zhang Yiping, chief physician of the Department of Medical Oncology , Cancer Hospital Affiliated to the University of Chinese Academy of Sciences ( Zhejiang Cancer Hospital ) , said : " When Hb is less than or equal to 100 g/L , EPO treatment can be started , and the conventional treatment plan can choose EPO 36000U or 40000U as the starting dose , 1 A course of treatment is 4-6 weeks .
The newly added weekly dosage of EPO 40000U intravenous drip in this guideline is more in line with the current medical environment .
Improving patient compliance , saving medical resources , and improving bed turnover are worthy of clinical promotion .
" Leave a message here
